 "After Sputnik-V, Russia to register second Covid-19 vaccine by Oct 15")
Russia expects to register a second potential vaccine against Covid-19 by October 15, the TASS news agency cited Russian consumer safety watchdog Rospotrebnadzor as saying on Tuesday.
The vaccine has been developed by Siberia’s Vector Institute, which completed early-stage human trials of the vaccine last week.
Russia registered its first vaccine candidate, developed by Moscow’s Gamaleya Institute, in August.
Late-stage trials, involving at least 40,000 people, are ongoing.
The vaccine has been developed by Siberia’s Vector Institute, which completed early-stage human trials of the vaccine last week.
Russia registered its first vaccine candidate, developed by Moscow’s Gamaleya Institute, in August.
Also Read
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%